ESTRO 2024 - Abstract Book

S1386

Clinical - Head & neck

ESTRO 2024

1.102 (0.772-1.702): p value = 0.645 0.992 (0.398 – 4.110): p value = 0.883 1.206 (0.663-2.220): p value = 0.392 1.704 (1.274-3.873): p value = 0.018 2.778 (1.330-5.092): p value = 0.009 1.087 (1.013-1.097): p value = <0.001 0.803 (0.776-0.943): p value = <0.001 1.543 (1.198-2.329): p value = 0.001 1.065 (0.609-1.722): p value = 0.870 0.790 (0.402-2.723): p value = 0.738 1.982 (1.338-3.443): p value = 0.021 11.779 (6.221-39.002): p value = <0.001 2.336 (1.309-4.201): p value = <0.001 1.409 (1.177-3.827): p value = 0.011 1.503 (1.019-2.109): p value = 0.026 Reference Reference

MD

PD

pT Stage

pT1

0.756 (0.575-1.509): p value = 0.409 0.773 (0.320-1.773): p value = 0.664 0.690 (0.265-2.498); p value = 0.711 1.035 (0.889-1.093): p value = 0.376 0.901 (0.878-0.994): p value = 0.006 1.409 (1.207-1.880): p value = 0.019 0.723 (0.499-1.631): p value = 0.503 0.410 (0.321-1.553): p value = 0.387 1.552 (0.630-2.927): p value = 0.221 17.022 (4.090-71.992): p value = <0.001 1.711 (1.202-2.987): p value = 0.039 1.330 (1.187-2.665): p value = 0.012 1.482 (1.032-2.558): p value = 0.017 Reference

pT2

pT3

pT4

DOI (mm)

Continuous

Margin (mm)

Continuous

PNI

Present

pN Stage

pN0

pN1

pN2a

pN2b

pN2c

pN3b

ENE

Present

LVI

Present

Conclusion:

Significant number of patients with OTC have LVI. Presence of LVI is a poor prognostic factor for OTC in this large number of large cohort. The presence of LVI may impact therapeutic decision-making algorithm. Patients with presence of LVI should be treated aggressively with adjuvant therapy after primary surgical resection. Further research should focus on the impact of adjuvant therapy in patients with LVI as the sole pathological risk factor.